Multiple Myeloma, A151804

This trial collects research data and samples from patients who experience immunotherapy side effects to store for use in future research studies. Studying research data and samples from patients who experience immunotherapy side effects may help researchers better understand how to predict, prevent, and treat these side effects.

Solid Tumor, ART0380C001 “ARTIOS”

A Phase I/IIa, Open-label, Multi-center Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy and in Combination to Patients with Advanced or Metastatic Solid Tumors.

Pancreas, Tempus Aries TP-CA-007

A Second Line Biobank Registry Platform Study in Oncology Patients with KRAS mutated CRC, NSCLC & PDAC. Reference arm study to evaluate ctDNA kinetics and dynamics in response to standard of care therapy in patients with relapsed and metastatic KRAS-mutated NSCLC to enable novel biomarker discovery and drug development.

Colorectal, Tempus Aries TP-CA-007

A Second Line Biobank Registry Platform Study in Oncology Patients with KRAS mutated CRC, NSCLC & PDAC. Reference arm study to evaluate ctDNA kinetics and dynamics in response to standard of care therapy in patients with relapsed and metastatic KRAS-mutated NSCLC to enable novel biomarker discovery and drug development.

Lung, Tempus Gemini TP-CA-002

GEMINI NSCLC Study is a non-interventional study that will be collecting clinical and molecular health information from patients with NSCLC who will receive longitudinal blood collection in addition to their standard of care therapy and disease surveillance with the goals of identifying the molecular evolution of lung cancer with standard of care therapy, and determining the utility of ctDNA dynamics to predict risk of recurrence and therapeutic outcomes.

Lung, Tempus Aries TP-CA-007

A Second Line Biobank Registry Platform Study in Oncology Patients with KRAS mutated CRC, NSCLC & PDAC. Reference arm study to evaluate ctDNA kinetics and dynamics in response to standard of care therapy in patients with relapsed and metastatic KRAS-mutated NSCLC to enable novel biomarker discovery and drug development.

Lung, Ovation-23-001

The objective of this study is to establish a biorepository and database of specimens to enable future research on the role of molecular genomics in the biological mechanisms of cancers, as well as to validate measures of molecular residual disease in these patient populations. 

Lung, MIRATI 849-017 “KRYSTAL 17”

A Phase 2 Trial of Combination Therapies with Adagrasib in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation

Breast, Ovation-23-001

The objective of this study is to establish a biorepository and database of specimens to enable future research on the role of molecular genomics in the biological mechanisms of cancers, as well as to validate measures of molecular residual disease in these patient populations.

Patient Newsletter 2024 October

Pages